INTRODUCTION
Non-Hodgkin's lymphoma (NHL) encompasses a group of hematologic malignancies of B and T cell origin. However, the majority of NHLs are B cell lymphomas and these can further be categorized as indolent or low grade, intermediate grade, and aggressive or high grade (1) (2) (3) . There are approximately 30,000-50,000 new cases of B cell lymphoma in the United States each year; a large proportion of diagnosed patients will eventually die of this disease despite conventional chemo-and radiotherapy as well as bone marrow transplantation (in refractory or relapsed NHL).
Since NHLs typically express one or more B cell markers, these markers can be used to target antibody-based cytotoxic agents. Although normal B cells will be destroyed, they are repopulated from stem cells lacking the targeted antigens. Alternatively, since B cell tumors are clonal, the immunoglobulin idiotype can be considered a tumor-specific marker. In mice with human lymphoma xenografts, antibodies conjugated to radionuclides, drugs, or toxins can be curative, particularly when combined with other therapies. These immunoconjugates are highly potent in vitro and in mice. However, because they carry a toxic moiety, their safety profile in humans must be carefully established. In the case of antibody toxin conjugates (immunotoxins, or ITs), these agents have displayed better antilymphoma activity at lower concentrations than did unconjugated antibodies both in vitro and in vivo. Early trials using ITs in patients have established the safe doses and the side effects, and efficacy must now be established in Phase II and III trials. Clearly, ITs have activity in humans but it remains to be determined whether they will improve the long-term prognosis for patients with NHL.
IMMUNOTOXINS
Two major antigens on B lymphoma cells have been used as targets; CD 19 and CD22. Antibodies against these two molecules have been conjugated to either ricin toxin (RT) (4) or its deglycosylated A chain (dgRTA) (5-8), or pokeweed antiviral protein (PAP) (9) . dgRTA Containing ITs (Fig. 1 ) CD 19 is expressed on all normal B cells from the pre-B cell stage to the plasma cell (10) (11) (12) , whereas CD22 appears on the mature B cell and disappears about the same time as CD19 on activated cells (10, 11) . CD19 and CD22 are expressed on greater than 90% and 60-80% of B lymphomas, respectively. Both anti-CD 19 and anti-CD22 have been conjugated to dgRTA and in the case of RFB4-anti-CD22, the monoclonal antibody (MAb) has been used as both intact IgGs (13) and Fab' (14) fragments. dgRTA is produced by deglycosylating the whole molecule of RT followed by separation of the two chains by size and affinity chromatography (15, 16 t-X-S-S--cYo 10 12 M (13) and is therefore approximately 10-fold more potent than its Fab' fragment conjugated to the same toxin (IC50 = 10 l1 M) (14) . In contrast, the HD37-IgG-RTA has an IC50 of 1-5 X 10 l M (13) and is 10-to 50-fold less cytotoxic than RFB4-IgG-dgRTA. Recombinant RTA (rRTA), lacking all carbohydrates, may also be used for chemical construction of ITs (18) (19) (20) .
Blocked Ricin (bRT)-Containing ITs
The anti-CD 19 monoclonal antibody B4 has been conjugated to bRT. The bRT is prepared by chemically blocking the galactose-binding sites on the ricin toxin B chain (RTB) with ligands containing N-linked oligosaccharides derived from fetuin (5) (6) (7) (8) 21 
